PTGX - Protagonist Therapeutics, Inc

QQQ $ 439.55 $ -0.26 (-0.06 %)

DIA $ 390.50 $ 1.74 (0.45 %)

SPY $ 517.10 $ 0.05 (0.01 %)

TLT $ 90.18 $ -0.55 (-0.61 %)

GLD $ 213.58 $ -0.63 (-0.29 %)

Previous Close

$ 27.11

Open

$ 26.52

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 25.74 - $ 28.40

52 Week Range

$ 13.72 - $ 33.34

Volume

774,633

Average Volume

Market Cap

1.72B

Beta (5Y Monthly)

$ 1.41

PE Ratio (TTM)

$ 10.64

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-07-2024	03-31-2024	10-Q
2	02-27-2024	12-31-2023	10-K
3	11-02-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	03-15-2023	12-31-2022	10-K
7	11-08-2022	09-30-2022	10-Q
8	08-04-2022	06-30-2022	10-Q
9	05-05-2022	03-31-2022	10-Q
10	02-28-2022	12-31-2021	10-K
11	11-03-2021	09-30-2021	10-Q
12	08-04-2021	06-30-2021	10-Q
13	05-04-2021	03-31-2021	10-Q
14	03-10-2021	12-31-2020	10-K
15	11-04-2020	09-30-2020	10-Q
16	08-06-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	03-10-2020	12-31-2019	10-K
19	11-06-2019	09-30-2019	10-Q
20	08-07-2019	06-30-2019	10-Q
21	05-08-2019	03-31-2019	10-Q
22	03-12-2019	12-31-2018	10-K
23	11-06-2018	09-30-2018	10-Q
24	08-07-2018	06-30-2018	10-Q
25	05-09-2018	03-31-2018	10-Q
26	03-07-2018	12-31-2017	10-K
27	11-07-2017	09-30-2017	10-Q
28	08-08-2017	06-30-2017	10-Q
29	05-10-2017	03-31-2017	10-Q
30	03-07-2017	12-31-2016	10-K
31	11-14-2016	09-30-2016	10-Q
32	09-15-2016	06-30-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

JMP Securities Maintains Market Outperform...
05/08/2024 18:09:56

JMP Securities analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raise...

Protagonist Therapeutics Q1 EPS $3.26, Sal...
05/07/2024 20:58:54

Protagonist Therapeutics Has Randomized 24...
03/26/2024 11:17:51

Protagonist Therapeutics Closes Worldwide ...
03/18/2024 11:12:53

HC Wainwright & Co. Maintains Buy on Prota...
03/11/2024 16:15:26

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $38 p...

JMP Securities Reiterates Market Outperfor...
03/11/2024 14:12:41

JMP Securities analyst Jonathan Wolleben reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and main...

Protagonist Therapeutics Announced A Late-...
03/11/2024 11:40:11

JNJ-2113 was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist ...

JP Morgan Maintains Overweight on Protagon...
02/28/2024 14:49:10

JP Morgan analyst Brian Cheng maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target...

HC Wainwright & Co. Reiterates Buy on Prot...
02/28/2024 12:27:04

HC Wainwright & Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $38 ...

Protagonist Therapeutics Q4 2023 GAAP EPS ...
02/27/2024 22:40:17

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate...

Protagonist Therapeutics Publishes Results...
02/21/2024 22:26:59

why-is-japanese-drugmaker-takeda-stock-trading-lower-today

Why Is Japanese Drugmaker Takeda Stock Tra...
02/01/2024 19:07:29

Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration dea...

12-health-care-stocks-moving-in-wednesdays-after-market-session

12 Health Care Stocks Moving In Wednesday'...
01/31/2024 21:31:06

Takeda And Protagonist Therapeutics, Inc. ...
01/31/2024 21:08:41

Protagonist Therapeutics Earned $10M Miles...
12/13/2023 12:42:37

Protagonist Reports 2-Year Follow Up Data ...
12/12/2023 14:08:26

Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerabilit...

The Latest Analyst Ratings for Protagonist...
11/03/2023 20:00:12

JMP Securities Maintains Market Outperform...
11/03/2023 19:49:44

JMP Securities analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raise...

Protagonist Therapeutics Announces Abstrac...
11/02/2023 13:23:51

Two oral presentations and three poster presentations elucidate new data relevant to rusfertide, a hepcidin mimetic with potent...

Capital One Initiates Coverage On Protagon...
10/30/2023 17:41:09

Capital One analyst Tim Chiang initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight rating.